Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusi

Phase 1

• Conditions: Systemic Lupus Erythematosus

• Registration Number: ITMCTR1900002316
• Lead Sponsor: anjing University of Chinese Medicine Affiliated Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria of SLE and the syndrome differentiation standard of TCM kidney deficiency and phlegm syndrome;
2. Aged 18 and 65 years old male and female;
3. Patients who have used or are using hormone therapy;
4. SLEDAI=5;
5. Informed consent, volunteering to be tested. The process of obtaining informed consent should be in accordance with GCP regulations.

Exclusion Criteria

1. Patients have combined with serious diseases such as infections and tumors;
2. With other rheumatisms such as rheumatoid arthritis, scleroderma, polymyositis, and Sjogren's syndrome;
3. The condition is critical and it is difficult to make a definitive assessment of the effectiveness of this trial;
4. Pregnant, lactating women;
5. Persons with intellectual or behavioral disorders unable to give informed consent;
6. Suspected or indeed have a history of alcohol and drug abuse;
7. According to the judgment of the investigator, other lesions that have the possibility of reducing the enrollment or complicating the enrollment, such as frequent changes in the working environment, are likely to cause loss of follow-up;
8. Allergies, such as those who have a history of allergies to two or more drugs or foods; or those who are known to be allergic to the ingredients.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SLEDAI;Metabolomics;Proteomics;blood pressure;